Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $44.99 | $0.90/mg | In stock | Jul 27 |
| vial | 100mg | $59.99 | $0.60/mg | In stock | Jul 27 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| Clear Cap | Apr 2026 | 99.9% | Freedom Diagnostics | — | Unverified | View |
| Blue Cap | Apr 2026 | 99.9% |
In FDA Category 1 for non-injectable routes only (restored May 14, 2026); injectable routes were removed from Category 2 on April 22, 2026 and are not authorized. Category 1 is FDA's “under evaluation” enforcement-discretion policy — not a finding of safety or efficacy, and not the 503A bulks list. Alongside Vasoactive Intestinal Peptide, GHK-Cu is one of only two peptides in Category 1 today.
Does Rescue Research USA sell GHK-Cu?
Yes — Rescue Research USA currently lists GHK-Cu in 2 variants starting at $59.99 ($0.60/mg).
Is Rescue Research USA's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Rescue Research USA's GHK-Cu, with the most recent showing 99.9% purity. Rescue Research USA holds an overall trust grade of C (73/100) across all 31 COAs on file.
What is Rescue Research USA's trust grade for GHK-Cu?
Rescue Research USA has an overall Disclosed Labs trust grade of C (73/100), computed from 31 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Rescue Research USA's listing at $0.60/mg. See the full GHK-Cu price comparison.
What is the FDA compounding status of GHK-Cu?
In FDA Category 1 for non-injectable routes only (restored May 14, 2026); injectable routes were removed from Category 2 on April 22, 2026 and are not authorized. Category 1 is FDA's “under evaluation” enforcement-discretion policy — not a finding of safety or efficacy, and not the 503A bulks list. Alongside Vasoactive Intestinal Peptide, GHK-Cu is one of only two peptides in Category 1 today. Sales tracked here are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| — |
| Unverified |
| View |
Disclosed Labs